Cuban President Miguel Díaz-Canel praised today on Twitter the upcoming start of clinical trials of the national drug against Alzheimer's, NeuralCIM (NeuroEPO) and remarked that Cuban science and innovation continue to contribute to the country's development.

Cuba reported today 43 new COVID-19 cases, 41 hospital discharges and no fatalities.

The Center for Molecular Immunology (CIM) is conducting two clinical trials—named CORVAXCIM and COREPOCIM—on COVID-19 convalescents, according to Sc.D. Mayra Ramos Suzarte, head of CIM’s clinical trials department, who explained that the first of these studies evaluates the safety and effects of the CIMAvax-EGF lung cancer vaccine in convalescents with respiratory disorders after infection by SARS-CoV-2.

Surveillance, prevention and control of zoonotic diseases, with priority for epidemiological actions are within Cuba's health programs, says a statement issued by the Ministry of Health (MINSAP).

At the Hermanos Ameijeiras Surgical Clinical Hospital in Havana, consultations began this Wednesday to classify patients with Alzheimer's disease for their subsequent inclusion in the Phase III clinical trial with the neuroprotective drug NeuralCIM (NeuroEPO).

The start-up in the Neonatology Unit of the Camilo Cienfuegos Provincial Hospital in Sancti Spiritus(central Cuba) of a state-of-the-art equipment to detect congenital heart disease in newborns is an important step in Cuba's strategy to further reduce the infant mortality rate per 1,000 live births.

Cuban ministry of public health ( MINSAP by its Spanish acronym)) reported today that a total of 9,974,887 people, equivalent to 90 % of the Cuban population, have completed the anti-COVID-19 vaccination program in the country, with the national immunogens Soberana 02, Soberana Plus and Abdala.

Cuba studied a total of 1,600 samples for surveillance, 36 were positive. The country accumulates 13,973,459 samples taken and 1,106,203 positive.

Cuban ministry of public health ( MINSAP by its Spanish acronym)) reported today that a total of 9,974,887 people, equivalent to 90 % of the Cuban population, have completed the anti-COVID-19 vaccination program in the country, with the national immunogens Soberana 02, Soberana Plus and Abdala.

Cuba studied a total of 2,274 samples for surveillance, 43 were positive for 1.9% positivity. The country accumulates 13,971,859 samples taken and 1,106,167 positive (7.9%).

We’d like to spread Cuba’s experience in Biotechnology as an example for the world said the executive director of the Tricontinental Institute for Social Research, Vijay Prashad.

A total 7,398,882 people in Cuba have received anti-COVID-19 booster doses, the Ministry of Public Health (MINSAP by its Spanish acronym) reported today on its website.

Cuba tested a total of 2,430 samples for surveillance, 22 of which were positive. The country accumulates 13, 964,854 samples taken and 1,106,045 positive.

Cuban Health Minister Jose Angel Portal Miranda supervised health care centers and other related services in the locality of Jobabo on Thursday as part of a governmental working visit to this Eastern province.